Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by lung scarring, fibrosis and finally respiratory failure. Currently, few treatment options are available for IPF and they only slow down disease progression and do not reverse fibrosis. There is a need for new therapeutic targets that aid in the management of the disease.